Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance
Xtant Medical Holdings (NYSE American: XTNT) has launched Trivium™, a next-generation demineralized bone matrix (DBM) allograft featuring advanced PureLoc™ Fiber Technology. The product combines three synergistic elements for enhanced structure, handling, and biological activity.
Trivium's unique design includes intertwined structures and interconnected porosity to support cell attachment and tissue ingrowth. The product utilizes Xtant's proprietary BacteRinse® processing method, which has been clinically proven to preserve bone morphogenetic proteins (BMPs) over two decades.
The new bone graft offers superior moldability for precise placement across various surgical applications and is now available through the company's nationwide network of independent agents.
Xtant Medical Holdings (NYSE American: XTNT) ha lanciato Trivium™, un innesto osseo demineralizzato (DBM) di nuova generazione che integra l'avanzata PureLoc™ Fiber Technology. Il prodotto combina tre elementi sinergici per migliorare struttura, maneggevolezza e attività biologica.
Il design unico di Trivium include strutture intrecciate e porosità interconnesse per favorire l'adesione cellulare e la crescita dei tessuti. Il prodotto utilizza il metodo di lavorazione proprietario di Xtant, BacteRinse®, clinicamente comprovato da oltre vent'anni per preservare le proteine morfogenetiche ossee (BMP).
Il nuovo innesto osseo offre una superiore modellabilità per un posizionamento preciso in diverse applicazioni chirurgiche ed è ora disponibile attraverso la rete nazionale di agenti indipendenti dell'azienda.
Xtant Medical Holdings (NYSE American: XTNT) ha lanzado Trivium™, un aloinjerto de matriz ósea desmineralizada (DBM) de próxima generación que cuenta con la avanzada tecnología de fibra PureLoc™. El producto combina tres elementos sinérgicos para mejorar la estructura, el manejo y la actividad biológica.
El diseño único de Trivium incluye estructuras entrelazadas y porosidad interconectada para favorecer la adhesión celular y el crecimiento tisular. El producto utiliza el método de procesamiento patentado de Xtant, BacteRinse®, clínicamente probado durante más de dos décadas para preservar las proteínas morfogenéticas óseas (BMP).
El nuevo injerto óseo ofrece una moldeabilidad superior para una colocación precisa en diversas aplicaciones quirúrgicas y ya está disponible a través de la red nacional de agentes independientes de la compañía.
Xtant Medical Holdings (NYSE American: XTNT)는 첨단 PureLoc™ 섬유 기술이 적용된 차세대 탈광물화 골 매트릭스(DBM) 동종 이식재 Trivium™을 출시했습니다. 이 제품은 구조, 취급성 및 생물학적 활성 향상을 위한 세 가지 시너지 요소를 결합합니다.
Trivium의 독특한 설계는 세포 부착과 조직 성장 지원을 위한 얽힌 구조와 상호 연결된 다공성을 포함합니다. 이 제품은 Xtant의 독자적인 BacteRinse® 처리 방식을 사용하며, 20년 이상 임상적으로 골형성단백질(BMP)을 보존하는 것으로 입증되었습니다.
새로운 골 이식재는 다양한 외과적 적용에서 정밀한 위치 지정을 위한 우수한 성형성을 제공하며, 현재 회사의 전국 독립 대리점 네트워크를 통해 구매할 수 있습니다.
Xtant Medical Holdings (NYSE American : XTNT) a lancé Trivium™, un allogreffe de matrice osseuse déminéralisée (DBM) de nouvelle génération intégrant la technologie avancée PureLoc™ Fiber. Ce produit combine trois éléments synergiques pour améliorer la structure, la maniabilité et l'activité biologique.
Le design unique de Trivium comprend des structures entrelacées et une porosité interconnectée pour favoriser l'attachement cellulaire et la croissance tissulaire. Le produit utilise la méthode de traitement propriétaire de Xtant, BacteRinse®, cliniquement prouvée depuis plus de vingt ans pour préserver les protéines morphogénétiques osseuses (BMP).
Cette nouvelle greffe osseuse offre une malléabilité supérieure pour un positionnement précis dans diverses applications chirurgicales et est désormais disponible via le réseau national d'agents indépendants de l'entreprise.
Xtant Medical Holdings (NYSE American: XTNT) hat Trivium™ eingeführt, ein neuartiges demineralisiertes Knochenmatrix-Allograft (DBM) mit fortschrittlicher PureLoc™-Fasertechnologie. Das Produkt kombiniert drei synergistische Elemente für verbesserte Struktur, Handhabung und biologische Aktivität.
Das einzigartige Design von Trivium umfasst verflochtene Strukturen und miteinander verbundene Porosität, um die Zellhaftung und das Gewebewachstum zu unterstützen. Das Produkt verwendet die firmeneigene BacteRinse®-Verarbeitung von Xtant, die klinisch seit über zwei Jahrzehnten nachweislich Knochenmorphogenetische Proteine (BMPs) erhält.
Das neue Knochenersatzmaterial bietet eine überlegene Formbarkeit für präzise Platzierung bei verschiedenen chirurgischen Anwendungen und ist jetzt über das landesweite Netzwerk unabhängiger Vertreter des Unternehmens erhältlich.
- Launch of innovative bone graft product expanding company's portfolio
- Proprietary BacteRinse® technology with 20-year clinical validation
- Product available immediately through nationwide distribution network
- None.
Insights
Xtant's new premium Trivium bone graft product expands portfolio with advanced technology, representing positive innovation in core business.
Xtant Medical's launch of Trivium™ represents a concrete advancement in their regenerative medicine portfolio. This premium bone graft combines three key elements through their proprietary PureLoc™ Fiber Technology, creating intertwined structures with interconnected porosity designed to support cell attachment and tissue ingrowth - critical factors for successful integration in bone grafting procedures.
The product's superior moldability enables precise placement across various surgical applications, while the company's established BacteRinse® processing method (clinically proven over two decades according to the company) preserves native bone morphogenetic proteins essential for initiating bone repair.
For Xtant Medical, this launch demonstrates continued innovation in their core bone grafting business. The immediate availability through their nationwide distribution network of independent agents indicates this is a full commercial rollout rather than just a development announcement.
While the article doesn't provide specific financial projections or market sizing, new product introductions with differentiated features and premium positioning are typically positive developments for medical technology companies focused on surgical solutions for spinal and orthopedic disorders.
Trivium is uniquely designed, featuring intertwined structures and interconnected porosity that support the attachment and proliferation of a variety of cell types, and designed to promote robust tissue ingrowth. This advanced composition creates an ideal environment for healing and regeneration.
With its superior moldability and handling characteristics, Trivium allows surgeons to place the graft with precision across a wide range of surgical applications.
Trivium is processed using Xtant's proprietary BacteRinse® method, clinically proven over two decades to preserve native bone morphogenetic proteins (BMPs). This ensures Trivium delivers a complete suite of bioavailable growth factors critical to initiating and supporting bone repair.
"Trivium represents a significant advancement in bone grafting technology," said Sean Browne, President and CEO of Xtant Medical. "By combining enhanced composition, high BMP retention, and versatile handling characteristics, Trivium provides surgeons with a dependable solution for a variety of surgical applications. We are confident that Trivium will deliver consistent, reliable outcomes for patients."
Trivium represents Xtant Medical's ongoing commitment to innovation in regenerative medicine, providing surgeons with a high-performance graft that supports optimal outcomes. Trivium is now available to the company's nationwide distribution network of independent agents.
About Xtant Medical Holdings, Inc.
Xtant Medical's mission of "honoring the gift of donation so that our patients can live as full and complete a life as possible" is the driving force behind our company. Xtant Medical Holdings, Inc. (www.xtantmedical.com) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers.
The symbols ™ and ® denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as "intends," ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' "continue," "future," ''will,'' "potential," similar expressions or the negative thereof, and the use of future dates. Forward-looking statements in this release include the Company's expectations regarding the performance of Trivium and outcomes for patients utilizing Trivium. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of newly launched products, such as Trivium, to gain market acceptance, perform as designed and intended, and meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; Xtant's ability to execute its strategic priorities and become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; its ability to implement successfully future growth initiatives and risks associated therewith; its ability to remain competitive and innovate, develop and introduce new products and the success of those products; its ability to engage and retain new and existing independent distributors and agents and qualified personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on its business, operating results and financial condition, especially when they affect key markets; the effect of tariffs, inflation, increased interest rates and other recessionary factors and supply chain disruptions; the effect of product sales mix changes on the Company's financial results; government and third-party coverage and reimbursement for Company products; the ability to obtain and maintain regulatory approvals and comply with government regulations; the effect of product recalls, defects and liability claims and other litigation to which the Company may be subject; the ability to maintain sufficient liquidity to fund its operations and obtain financing on favorable terms or at all; and other factors. Additional risk factors are contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC) on March 6, 2025 and subsequent SEC filings by the Company. Investors are encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement.
View original content to download multimedia:https://www.prnewswire.com/news-releases/xtant-medical-launches-trivium-advanced-bone-graft-for-superior-performance-302435052.html
SOURCE Xtant Medical Holdings, Inc.
FAQ
What are the key features of Xtant Medical's new Trivium bone graft (XTNT)?
How does Xtant Medical's Trivium bone graft (XTNT) enhance surgical procedures?
What is the distribution strategy for Xtant Medical's Trivium bone graft?
What technology does Xtant Medical use to preserve BMPs in Trivium?
